Cardiovascular Health

The use of certain drugs, such as statins, may lead to rhabdomyolysis.

Physicians often overlook those with lower BMIs who have nonalcoholic fatty liver disease and lower rates of other comorbidities, investigators say.

Asundexian was granted FDA Fast Track Designation based on a phase 2 study evaluating its safety and efficacy combined with antiplatelet therapy in patients following an acute, non-cardioembolic ischemic stroke.

The findings suggest that the broad use of race as a factor for providing certain health interventions and treatments should be reconsidered, investigators say.

Scientific abstracts also address findings on cardiovascular disease and population, the connection between COVID-19 and HF, and links between prognosis and marital status.

The advisory, published in Circulation, is a call to action for a cultural shift to identify and remove barriers.

The recommendations apply to individuals who are already taking the maximum dose of statins.

Results from the DELIVER and DAPA-HF phase 3 trials demonstrate AstraZeneca’s Farxiga’s efficacy in heart failure, regardless of ejection fraction.

Individuals who are not vaccinated with pre-existing diabetes, heart artery disease, or high blood pressure had a 2- to 3-fold increased risk of death, investigators say.

Spending 1 hour less sitting a day and increasing light physical activity helps prevent diseases, investigators find.

Individuals with college debt have a higher risk of cardiovascular illness, undermining the typical benefits of a post-secondary education, data indicate.

Mavacamten is a first-in-class selective allosteric modulator of beta cardiac myosin ATPase for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Analysis results show taking iscosapent ethyl reduces the potential for CV death, coronary revascularization, hospitalization for unstable angina, myocardial infarction, and stroke by 35%.

Cytisinicline demonstrated significantly better quit rates than placebo in 6 and 12 week trials.

Data show that 89% of individuals treated for persistent AFiB remained symptom-free for up to 15 months after using the product.

Women in the study had higher rates of urgent procedures and were in poorer health when they received surgery.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin designed to decrease contractile function and improve VO2 in patients with obstructive hypertrophic cardiomyopathy.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

Analysis indicates that quitting provides roughly the same benefit as taking 3 medications together.

Asthma contributed most to the risk of high blood pressure and coronary heart disease.

Pharmacy Quality Alliance's new benchmark evaluates adherence to medications for diabetes, high cholesterol, and hypertension.

A recent meta-analysis of statins showed that prevalence of statin intolerance is less than 10%, according to the panel.

Drug meets primary endpoint at 50 mg with reduction in low-density lipoprotein levels from the baseline in the ETESIAN phase 2b trial

Recent studies demonstrated that renal failure, proteinuria, and histologic renal lesions can be prevented by mineralocorticoid receptor antagonists.

Lipitor is an inhibitor of HMG-CoA reductase indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels.